Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 349 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Gleevec (Imatinib mesylate) Clear all

Conditions: Leukemia
Interventions: GM-K562 cell vaccine, Interferon alfa, Sargramostim; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Leukemia
Interventions: imatinib mesylate, gene expression analysis, mutation analysis, polymerase chain reaction, flow cytometry, biopsy; Drug · Genetic · Other + 1 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 4
States / cities: Buffalo, New York • Durham, North Carolina • Cleveland, Ohio

Conditions: Choroidal Neovascularization
Interventions: Imatinib Mesylate /Ranibizumab; Drug
Lead sponsor: Vitreous -Retina- Macula Consultants of New York; Other
Eligibility: 51 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Phase Chronic Myelogenous Leukemia
Interventions: Asciminib 40 MG, Asciminib 40 MG Twice Daily, Asciminib 80 MG daily, Imatinib, Nilotinib, Dasatinib; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 5
States / cities: Detroit, Michigan • Buffalo, New York • New York, New York + 2 more

Conditions: Uterine Cancer
Interventions: Imatinib Mesylate, Paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gastrointestinal Stromal Tumor
Interventions: imatinib mesylate, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Prostate Cancer
Interventions: Docetaxel, Imatinib Mesylate, Leuprolide, Goserelin Acetate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual Disease, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Interventions: Dasatinib, Imatinib Mesylate, Nilotinib, Ruxolitinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: Metformin, Imatinib; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 45 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Leukemia
Interventions: arsenic trioxide, imatinib mesylate; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 3
States / cities: Los Angeles, California • Tampa, Florida • Portland, Oregon

Conditions: Leukemia
Interventions: recombinant interferon alfa, imatinib mesylate; Biological · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 2
States / cities: Chicago, Illinois • Portland, Oregon

Conditions: Chronic Myelogenous Leukemia
Interventions: decitabine (5-aza-2'deoxycytidine); Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 7
States / cities: Duarte, California • Escondido, California • Los Angeles, California + 4 more

Conditions: PAH
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Aurora, Colorado • Weston, Florida • Baltimore, Maryland + 5 more

Conditions: Myelogenous Leukemia, Chronic
Interventions: nilotinib, imatinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 846 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 31
States / cities: Los Angeles, California • San Diego, California • Vallejo, California + 27 more

Conditions: Asthma
Interventions: MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years and older
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 29
States / cities: Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more

Conditions: Leukemia
Interventions: Peptide Vaccine (PR1 Peptide), Peginterferon alfa-2b, Imatinib, GM-CSF; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Polycythemia Vera
Interventions: Gleevec; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Myelogenous Leukemia
Interventions: Gleevec (imatinib), valproic acid; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Ovarian Dysgerminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Ovarian Germ Cell Tumor, Stage II Malignant Testicular Germ Cell Tumor, Stage II Ovarian Germ Cell Tumor, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Testicular Seminoma
Interventions: imatinib mesylate, therapeutic conventional surgery, laboratory biomarker analysis; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 15 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Myeloid Leukemia, Blast Crisis, Acute Myeloid Leukemia
Interventions: Imatinib Mesylate, CLAG; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Kidney Cancer
Interventions: gemcitabine hydrochloride, imatinib mesylate, gene expression analysis, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Leukemia
Interventions: filgrastim, cladribine, cytarabine, imatinib mesylate; Biological · Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Gastrointestinal Stromal Tumors
Interventions: Ripretinib, Sunitinib; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 43
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 38 more

Conditions: Mucosal Melanoma, Acral/Lentiginous Melanoma, Chronically Sun Damaged Melanomas
Interventions: Imatinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 5
States / cities: Denver, Colorado • Tampa, Florida • Chicago, Illinois + 2 more

Search by objective public record fields.

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy

Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Drug-drug Interaction Study With Metformin and Imatinib

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Pulmonary Hypertension and Imatinib

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

Treatment of Polycythemia Vera With Gleevec

A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma